A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, synergistically enhances radiation sensitivity in human cervical cancer cells

Anti-Cancer Drugs

Volumn 23, Issue 1, 2012, Pages 43-50

  Woo, Soo Jung ^a   Kim, Min Jung ^a,c   Kim, Rae Kwon ^a   Yoon, Chang Hwan ^a   Lim, Eun Jung ^a   An, Sungkwan ^b   Suh, Yongjoon ^a   Song, Ji Young ^a   Kim, In Gyu ^c   Cho, Cheon Gyu ^a   Lee, Su Jae ^a  

^a Hanyang University   (South Korea)

^b Konkuk University   (South Korea)

^c Korea Atomic Energy Research Institute   (South Korea)

Author keywords

2 pyrone derivative; ionizing radiation; mitochondrial cell death; reactive oxygen species

Indexed keywords

2 PYRONE DERIVATIVE; 5 BROMO 3 (3 HYDROXYPROP 1 YNYL) 2H PYRAN 2 ONE; ALPHA TUBULIN; BETA ACTIN; CASPASE 3; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAK; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN CONFORMATION; RADIOSENSITIVITY; UTERINE CERVIX CANCER;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MITOCHONDRIA; PYRANS; PYRONES; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 82555164996     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834a66ef     Document Type: Article

References (35)

1. Hahn WC. Cancer: surviving on the edge. Cancer Cell 2004; 6:215-222. (Pubitemid 39222034)
2. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer 2004; 90:1297-1301. (Pubitemid 38586250)
3. Wheeler JA, Stephens LC, Tornos C, Eifel PJ, Ang KK, Milas L, et al. ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1995; 32: 1487-1493.
4. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor developmentand contributes to radiation resistance in gliomas. Cancer Cell 2010; 18:619-629.
5. Marchand V, Decaudin D, Servois V, Kirova YM. Concurrent radiation therapy and lenalidomide in myeloma patient. Radiother Oncol 2008; 87:152-153.
6. Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006; 80:207-213. (Pubitemid 44314020)
7. Trachootham D, LuW, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008; 10:1343-1374.
8. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005; 10:1881-1896. (Pubitemid 40529044)
9. Singh KK. Mitochondria damage checkpoint, aging, and cancer. Ann N Y Acad Sci 2006; 1067:182-190. (Pubitemid 43806323)
10. Byun JY, Kim MJ, Eum DY, Yoon CH, Seo WD, Park KH, et al. Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol 2009; 76:734-744.
11. Spitz DR, Azzam EI, Li JJ, Gius D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 2004; 23: 311-322. (Pubitemid 38881814)
12. Park MT, Kim MJ, Kang YH, Choi SY, Lee JH, Choi JA, et al. Phytosphingosine in combination with ionizing radiation enhances apoptotic cell death in radiation-resistant cancer cells through ROS-dependent and -independent AIF release. Blood 2005; 105:1724-1733.
13. Faulkner DJ. Marine natural products. Nat Prod Rep 2001; 18:1-49. (Pubitemid 32160982)
14. Jensen PR, FenicalW. Strategies for the discovery of secondary metabolites from marine bacteria: ecological perspectives. Annu Rev Microbiol 1994; 48:559-584. (Pubitemid 24334109)
15. McGlacken GP, Fairlamb IJ. 2-Pyrone natural products and mimetics: isolation, characterisation and biological activity. Nat Prod Rep 2005; 22:369-385. (Pubitemid 40885717)
16. Dickinson JM. Microbial pyran-2-ones and dihydropyran-2-ones. Nat Prod Rep 1993; 10:71-98.
17. Thaisrivongs S, Romero DL, Tommasi RA, Janakiraman MN, Strohbach JW, Turner SR, et al. Structure-based design of HIV protease inhibitors: 5,6- dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors. J Med Chem 1996; 39:4630-4642. (Pubitemid 26382848)
18. Poppe SM, Slade DE, Chong KT, Hinshaw RR, Pagano PJ, Markowitz M, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997; 41:1058-1063. (Pubitemid 27194185)
19. Turner SR, Strohbach JW, Tommasi RA, Aristoff PA, Johnson PD, Skulnick HI, et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41:3467-3476. (Pubitemid 28406555)
20. Perchellet JP, Newell SW, Ladesich JB, Perchellet EM, Chen Y, Hua DH, et al. Antitumor activity of novel tricyclic pyrone analogs in murine leukemia cells in vitro. Anticancer Res 1997; 17:2427-2434. (Pubitemid 27352631)
21. Hileman EO, Liu JS, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemoth Pharm 2004; 53:209-219. (Pubitemid 38293718)
22. Fennell DA, Corbo M, Pallaska A, Cotter FE. Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species. Br J Cancer 2001; 84:1397-1404. (Pubitemid 32522111)
23. Park MT, Kang JA, Choi JA, Kang CM, Kim TH, Bae S, et al. Phytosphingosine induces apoptotic cell death via caspase 8 activation and Bax translocation in human cancer cells. Clin Cancer Res 2003; 9:878-885. (Pubitemid 36182628)
24. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004; 3:294-300. (Pubitemid 39552423)
25. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55:319-321.
26. Suzuki K, Kuwahara A, Yoshida H, Fujita S, Nishikiori T, Nakagawa T. NF00659A1, A2, A3, B1 and B2, novel antitumor antibiotics produced by Aspergillus sp. NF 00659. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 1997; 50: 314-317. (Pubitemid 27223121)
27. Kondoh M, Usui T, Kobayashi S, Tsuchiya K, Nishikawa K, Nishikiori T, et al. Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett 1998; 126:29-32. (Pubitemid 28142968)
28. Jia L, Patwari Y, Srinivasula SM, Newland AC, Fernandes-Alnemri T Alnemri ES, et al. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene 2001; 20:4817-4826. (Pubitemid 32803152)
29. Porcelli AM, Ghelli A, Zanna C, Valente P, Ferroni S, Rugolo M. Apoptosis induced by staurosporine in ECV304 cells requires cell shrinkage and upregulation of Cl-conductance. Cell Death Differ 2004; 11:655-662. (Pubitemid 38786713)
30. Lin PH, Pan Z, Zheng L, Li N, Danielpour D, Ma JJ. Overexpression of Bax sensitizes prostate cancer cells to TGF-beta induced apoptosis. Cell Res 2005; 15:160-166. (Pubitemid 41653938)
31. Lin Y, Kokontis J, Tang F, Godfrey B, Liao S, Lin A, et al. Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol 2006; 26:1908-1916.
32. Cataldi A. Cell responses to oxidative stressors. Curr Pharm Des 2010; 16:1387-1395.
33. Pelicano H, Carney D, Huang PROS. stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7:97-110. (Pubitemid 38736063)
34. Carmody RJ, Cotter TG. Signalling apoptosis: a radical approach. Redox Rep 2001; 6:77-90. (Pubitemid 32519815)
35. Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 2008; 74:793-806.